Previous close | 2.7000 |
Open | 2.7000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 47.00 |
Expiry date | 2025-01-17 |
Day's range | 2.7000 - 2.7000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicine has published results from a positive pha
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatment indicated for EoE in the U.S. for this age group TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results from a positive Phase 3 trial for Dupixent
(Bloomberg) -- Sanofi SA has called for initial bids for its $20 billion consumer health division, as the French pharmaceutical giant simultaneously moves forward with preparations for a possible listing of the business, according to people familiar with the matter. Most Read from BloombergYouTuber Dr Disrespect Was Allegedly Kicked Off Twitch for Messaging MinorTrump Could Actually Lose Florida. Here’s Why.Volkswagen Invests $5 Billion in EV Startup Rivian to Form Joint VentureNvidia Rout Takes